Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
145 hedge funds and large institutions have $911M invested in Sage Therapeutics in 2016 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 69 increasing their positions, 28 reducing their positions, and 27 closing their positions.
146% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 28
45% more call options, than puts
Call options by funds: $66.8M | Put options by funds: $46.1M
4% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 27
1% more funds holding
Funds holding: 144 → 145 (+1)
2% less capital invested
Capital invested by funds: $933M → $911M (-$21.2M)
30% less funds holding in top 10
Funds holding in top 10: 10 → 7 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$21.1M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$13.9M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$13.2M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$12M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$51.8M |
| 2 |
DM
Deerfield Management
New York
|
-$35.7M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$33.8M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$12.3M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.17M |
SAGE Hedge Fund Activity: Q2 2016 in Review
145 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2016, worth a combined $911M — down 2.3% from $933M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new SAGE positions and 27 closed out — a net gain of 1 holder — while 69 added to existing stakes and 28 trimmed.
The largest buyer was Marshall Wace, adding an estimated $21.1M. The largest seller was Visium Asset Management, cutting an estimated $51.8M.
- 145 institutional investors held Sage Therapeutics (SAGE) as of Q2 2016, up from 144 in Q1 2016.
- Funds reported $911M of Sage Therapeutics stock for Q2 2016, down 2.3% quarter-over-quarter.
- 28 funds opened new Sage Therapeutics positions in Q2 2016 and 27 closed out, a net change of +1 holder.
- The largest Sage Therapeutics buyer in Q2 2016 was Marshall Wace, an estimated $21.1M added.
- The largest Sage Therapeutics seller in Q2 2016 was Visium Asset Management, an estimated $51.8M sold.
Based on aggregated 13F filings for Q2 2016.